QIAGEN N.V. announced the debut of QIAsymphony Connect, the next generation of QIAGEN’s widely adopted automated nucleic acid purification platform, at the 2025 AMP (Association for Molecular Pathology) annual meeting from November 11-15 in Boston.
The first public introduction of QIAsymphony Connect builds on more than 3,000 cumulative placements at the end of 2024 of the first-generation version, with the new generation designed to support liquid biopsy applications with enhanced speed, sample traceability and digital connectivity for labs.
Alongside QIAsymphony Connect, QIAGEN will also highlight at the AMP meeting a series of product innovations and updates to key partnerships in precision oncology.
QIAsymphony Connect introduces a range of significant improvements that enhance performance, speed and connectivity across various diagnostic and research workflows:
- An improved elution process minimizes intrinsic dead volume, yielding higher nucleic acid concentrations and maximizing recovery from large sample volumes.
- Enables up to 50% more samples in specific liquid biopsy protocols, boosting productivity and output without compromising quality.
- Designed for workflows such as MRD monitoring, where processing large sample volumes and achieving small elution volumes are critical for early detection.
- Automated 2D barcode scanning for both sample and eluate tubes ensures reliable end-to-end tracking.
- Integrates with LIMS and QIAsphere, QIAGEN’s cloud-based platform for remote monitoring and workflow optimization.
- Supports greater scalability and integration across laboratory processes.
QIAsymphony Connect has been made available to selected customers through an early access program ahead of full commercial release in mid-2026.
QIAGEN will showcase advancements across its Sample to Insight workflows, including early-access data and developments from two major precision oncology partnerships.
- A joint workshop with Element Biosciences on November 12 will feature early-access data from a study led and presented by Dr. Pinar Uysal-Onganer, an associate professor at the University of Westminster, demonstrating an efficient, scalable, comprehensive genomic profiling workflow for characterizing breast cancer FFPE samples using the QIAseq xHYB Trinity CGP on the Element Biosciences Trinity technology, together with CLC Genomics Workbench and QCI Interpret. Commercial launch is anticipated in early 2026.
- Data from the collaboration with Myriad Genetics Inc. will also be presented at AMP. The two companies are working together to advance testing for homologous recombination deficiency (HRD), a genetic condition that may make certain cancers more responsive to therapy. Early results from the QIAseq xHYB HRD Panel (intended for research applications), used in a Sample to Insight workflow, demonstrate high concordance with Myriad Genetics’ MyChoice CDx assay. Full commercialization (excluding Japan) is expected in early 2026.
- The QIAseq xHYB HRD Panel can be combined with the QIAseq xHYB CGP Panel to enable comprehensive genomic profiling and advanced HRD detection within a single hybrid-capture workflow. This combined assay supports simultaneous analysis of SNVs, indels and CNVs across 724 cancer-relevant genes, while also assessing key therapy biomarkers, including BRCA1/2, HRD, MSI and TMB.
To learn more about QIAGEN’s activities at AMP 2025, including workshops and presentations, visit www.qiagen.com/AMP2025.
